Skip to main content

Overview

Event Details

BridgeBio shares Phase 2 data for infigratinib in achondroplasia

March 6, 2023 7:30 AM EST

Webcast (opens in new window)
BBIO – infigratinib – PROPEL2 Topline Results (opens in new window)

Stay Informed.

COMPANY

About Us opens in new window
Careers opens in new window
Investors opens in new window
Legal Policies opens in new window

INSIGHTS

On Rare Podcast ↗ opens in new window
News opens in new window

SCIENCE

Clinical Trial Info opens in new window
Presentations & Publications opens in new window
Grants & Funding opens in new window

MEDICINES & PIPELINE

Pipeline opens in new window
Attruby^® (acoramidis) ↗ opens in new window
NULIBRY^® (fosdenopterin) ↗ opens in new window

PATIENTS

Stories opens in new window
Access opens in new window
Support opens in new window

SOCIAL

LinkedIn ↗ opens in new window
X ↗ opens in new window
Facebook ↗ opens in new window
Instagram ↗ opens in new window
Youtube ↗ opens in new window
Tiktok ↗ opens in new window

Bridgebio Logo

This site is intended for U.S. residents.
BridgeBio, Attruby, the Attruby logo, ForgingBridges, and the ForgingBridges logo are trademarks of BridgeBio Pharma, Inc. All other trademarks are property of their respective owners.

© 2026 BridgeBio Pharma Inc. - All rights reserved

Powered By Q4 Inc. 5.177.0.3 (opens in new window)